Huahui Health

What Huahui Health does

Huahui Health is a clinical-stage Chinese biopharmaceutical company founded in 2015 in Beijing's Life Science Park, focused on the R&D of innovative therapeutics for serious digestive and liver diseases, with an expanding oncology portfolio. The company's scientific foundation rests on co-founder Dr. Wenhui Li's 2012 discovery of NTCP as the functional receptor for HBV/HDV, which enabled the development of Libevitug (HH-003), the first-in-class monoclonal antibody targeting the PreS1 domain of HBV/HDV large envelope protein and the first approved treatment for chronic HDV infection in China following NMPA conditional approval in January 2026. Huahui operates four proprietary technology platforms: the NTCP-based antiviral and liver metabolism drug evaluation platform, the ACTab® pH-dependent antibody development platform (combining AI, antibody engineering, and high-throughput screening), the PolyBoost™ bispecific and multi-specific antibody engineering platform, and a biologics inhalation and nasal spray platform capable of producing ultra-high molecular weight protein formulations. The pipeline comprises approximately 12 candidates spanning viral hepatitis (HH-006 for chronic HBV, HH-1270 oral NTCP inhibitor), oncology (HH-009 FGF19 antibody for HCC, HH160 trispecific for solid tumors, HH019 CD98 ADC, HH268 T cell engager for AML, HB1313 for cancer cachexia), and infectious disease (HH-120 inhaled COVID prophylaxis).

Name

Huahui Health

Legal name

华辉安健（北京）生物科技有限公司

Website

https://huahuihealth.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

Huahui Health is a Beijing-based clinical-stage biopharmaceutical company developing first-in-class antibody and small-molecule therapeutics for viral hepatitis (HBV/HDV), liver cancer, and oncology, anchored by Libevitug, the first approved HDV treatment in China.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)

akta.pro secondary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

Keywords

• Biopharmaceutical drug development
• Monoclonal antibody therapeutics
• Hepatitis B therapeutics
• Oncology drug pipeline
• Viral hepatitis treatment

Headquarters

HQ city

Changping

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Product Sales: Sales of approved pharmaceutical products, primarily Libevitug (Huayunol) for chronic HDV infection. The product is distributed through pharmaceutical supply chains and hospitals for clinical use.
2. Licensing and Milestone Payments: Upfront payments, option exercise fees, development/regulatory/sales milestone payments, and tiered royalties from partnership agreements such as the BeOne Medicines deal for HH160 ($20M upfront + $100M option + up to $1.9B milestones + royalties).
3. Clinical Development Services: Collaboration with healthcare institutions and clinical trial sponsors for drug development services, including trials for HBV, HDV, and oncology programs.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Huahui Health is a biopharmaceutical company engaged in the research, development, and commercialization of innovative drugs for digestive diseases including viral hepatitis (HBV/HDV) and oncology indications such as liver cancer, pancreatic cancer, and hematological malignancies. The company's core focus is on monoclonal antibody-based therapies derived from the scientific discovery of NTCP as the functional receptor for HBV and HDV. With one approved product (Libevitug/Huayunol for chronic HDV infection) and a pipeline of 12+ drug candidates across antiviral and oncology areas, the company operates proprietary R&D platforms including the PolyBoost™ multispecific antibody engineering platform, ACTab® pH-dependent antibody platform, and biologics inhalation/nasal spray formulation platform.

Product overview

Huahui Health is a biopharmaceutical company with one marketed product (Libevitug) and a diversified pipeline of innovative drug candidates spanning antiviral, oncology, and metabolic disease areas. The company's core products include HH-003/Libevitug (first-in-class anti-HDV antibody approved in China), HH-006 (Fc-engineered anti-HBV antibody), HH-1270 (oral NTCP inhibitor), and multiple oncology candidates including HH-009 (FGF19 antibody for HCC), HH160 (trispecific antibody for solid tumors), HH019 (CD98 ADC), HH268 (TCE for AML), and HB1313 (bispecific for cancer cachexia). The company also operates four proprietary technology platforms: NTCP-based antiviral evaluation platform, ACTab pH-dependent antibody platform, PolyBoost multi-specific antibody platform, and biologics inhalation/nasal spray platform.

Differentiator

Problem solved

Functional benefit

Brands

• Huayunol (华优诺): Brand name for Libevitug (立贝韦塔单抗) injection in China
• Libevitug
• PolyBoost
• ACTab

Products and services

• Libevitug (Libevitug Injection / Huayunol, 立贝韦塔单抗 / 华优诺) A first-in-class, fully human IgG1 monoclonal antibody (HH-003) targeting the PreS1 domain of HBV/HDV large envelope protein. It blocks viral entry into hepatocytes by preventing binding to the NTCP receptor. Conditionally approved by China NMPA in January 2026 for the treatment of chronic HDV infection in adults with or without compensated cirrhosis. Administered via intravenous infusion in hospital and clinical settings at a recommended dosage of 10 mg/kg every 2 weeks (with potential increase to 20 mg/kg based on individual circumstances). International non-proprietary name: Libevitug; China brand name: Huayunol.
• HH160 HH160 is a novel symmetrical hexavalent trispecific antibody simultaneously targeting PD-1, CTLA-4, and VEGF-A for the treatment of solid tumors, developed on the company's proprietary PolyBoost™ platform. The "three-in-one" mechanism is intended to enhance therapeutic efficacy, achieve tumor-specific drug distribution, improve dosing convenience, and reduce treatment-related side effects. Global exclusive development, manufacturing, and commercialization rights have been contracted to BeOne Medicines under an option, license and collaboration agreement valued at $20 million upfront + $100 million option exercise + up to $1.9 billion in development/regulatory/sales milestones plus tiered royalties (total potential $2.02 billion). Preclinical results were presented at AACR 2025.

Quantifiable outcome

• Combined response rate of 44.1% at Week 48 in Phase IIb trial for chronic HDV infection
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core, regional and minor.

• BeOne MedicinescoreStrategic or Co-development Partner · 27 April 2026Global exclusive option, license and collaboration agreement for HH160, a novel trispecific antibody targeting PD-1, CTLA-4, and VEGF-A for oncology immunotherapy. BeOne Medicines pays $20M upfront, $100M upon option exercise, up to $1.9B in development/regulatory/sales milestones, plus tiered royalties. BeOne receives exclusive worldwide rights to develop, manufacture, and commercialize HH160. Parties also discussing BeOne's potential participation in Huahui Health's future financing activities.
• Pakistan Government / Federal Ministry of HealthregionalStrategic or Co-development Partner · 30 January 2026Pakistan's Federal Minister for Health convened meeting with Huahui Health and IQVIA Pakistan to establish local production of Libevitug (HH-003). Government pledged to facilitate partnership between Huahui Health and a Pakistani pharmaceutical manufacturer to enable technology transfer and affordable patient access for HDV therapy.
• IQVIA PakistanminorImplementation/ SI/ Consulting Partner · 30 January 2026Collaboration with Huahui Health and Pakistan government for local production of Libevitug (HH-003) and HDV therapy technology transfer.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Market position

Competitive moat5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/hhh-bio

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Huahui Health